Gastrointestinal bleed mortality disparities in patients with atrial fibrillation: A cross-sectional analysis

Enkhtsogt Sainbayar1, Ramzi Ibrahim2, Sangkyu Noh1

  • 1Department of Medicine University of Arizona Tucson Tucson Arizona USA.

Journal of Arrhythmia
|January 16, 2025
PubMed

Insights

Gastrointestinal bleeding deaths in patients with atrial fibrillation (AF) increased significantly from 1999-2020, with higher rates in males, White populations, and rural areas. Targeted interventions are needed for these vulnerable groups.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Public Health

Background:

  • Gastrointestinal bleeding (GIB) is a significant concern for patients with atrial fibrillation (AF) due to anticoagulation therapy.
  • Understanding disparities in GIB-related mortality is crucial for effective public health strategies.

Purpose of the Study:

  • To assess trends and disparities in gastrointestinal bleeding (GIB)-related mortality among decedents with atrial fibrillation (AF) in the United States.
  • To identify demographic and geographic factors associated with increased GIB mortality in the AF population.

Main Methods:

  • Utilized CDC WONDER database for GIB mortality data in AF patients (1999-2020).
  • Analyzed decedent demographic information from death certificates, including age, sex, race, ethnicity, and residence.
  • Calculated age-adjusted mortality rates (AAMRs) and estimated annual percentage change (APC) using log-linear regression.

Main Results:

  • Overall GIB mortality in AF decedents rose from 0.12 in 1999 to 0.21 in 2020 (APC +4.8% from 2009-2020).
  • Higher mortality rates were observed in males, White populations, and individuals residing in rural areas compared to females, Black populations, and urban areas.
  • Mortality increased significantly in urban regions after 2009 (APC +4.83%) and consistently in rural regions (APC +4.08%). The Northeast US had the highest mortality rate.

Conclusions:

  • Significant disparities in GIB mortality exist among AF decedents in the US.
  • Findings highlight the urgent need for targeted interventions to reduce GIB risks in vulnerable patient subgroups.
  • Further research into the specific drivers of these disparities is warranted to inform clinical practice and public health policy.
Abstract